Cargando…

Human Immunodeficiency Virus Type-1 (HIV-1) Continues to Evolve in Presence of Broadly Neutralizing Antibodies More than Ten Years after Infection

BACKGROUND: The evolution of HIV-1 and its immune escape to autologous neutralizing antibodies (Nabs) during the acute/early phases of infection have been analyzed in depth in many studies. In contrast, little is known about neither the long-term evolution of the virus in patients who developed broa...

Descripción completa

Detalles Bibliográficos
Autores principales: Chaillon, Antoine, Braibant, Martine, Hué, Stéphane, Bencharif, Samia, Enard, David, Moreau, Alain, Samri, Assia, Agut, Henri, Barin, Francis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3431314/
https://www.ncbi.nlm.nih.gov/pubmed/22957000
http://dx.doi.org/10.1371/journal.pone.0044163
_version_ 1782242061731233792
author Chaillon, Antoine
Braibant, Martine
Hué, Stéphane
Bencharif, Samia
Enard, David
Moreau, Alain
Samri, Assia
Agut, Henri
Barin, Francis
author_facet Chaillon, Antoine
Braibant, Martine
Hué, Stéphane
Bencharif, Samia
Enard, David
Moreau, Alain
Samri, Assia
Agut, Henri
Barin, Francis
author_sort Chaillon, Antoine
collection PubMed
description BACKGROUND: The evolution of HIV-1 and its immune escape to autologous neutralizing antibodies (Nabs) during the acute/early phases of infection have been analyzed in depth in many studies. In contrast, little is known about neither the long-term evolution of the virus in patients who developed broadly Nabs (bNabs) or the mechanism of escape in presence of these bNabs. RESULTS: We have studied the viral population infecting a long term non progressor HIV-1 infected patient who had developed broadly neutralizing antibodies toward all tier 2/3 viruses (6 clades) tested, 9 years after infection, and was then followed up over 7 years. The autologous neutralization titers of the sequential sera toward env variants representative of the viral population significantly increased during the follow-up period. The most resistant pseudotyped virus was identified at the last visit suggesting that it represented a late emerging escape variant. We identified 5 amino acids substitutions that appeared associated with escape to broadly neutralizing antibodies. They were V319I/S, R/K355T, R/W429G, Q460E and G/T463E, in V3, C3 and V5 regions. CONCLUSION: This study showed that HIV-1 may continue to evolve in presence of both broadly neutralizing antibodies and increasing autologous neutralizing activity more than 10 years post-infection.
format Online
Article
Text
id pubmed-3431314
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-34313142012-09-06 Human Immunodeficiency Virus Type-1 (HIV-1) Continues to Evolve in Presence of Broadly Neutralizing Antibodies More than Ten Years after Infection Chaillon, Antoine Braibant, Martine Hué, Stéphane Bencharif, Samia Enard, David Moreau, Alain Samri, Assia Agut, Henri Barin, Francis PLoS One Research Article BACKGROUND: The evolution of HIV-1 and its immune escape to autologous neutralizing antibodies (Nabs) during the acute/early phases of infection have been analyzed in depth in many studies. In contrast, little is known about neither the long-term evolution of the virus in patients who developed broadly Nabs (bNabs) or the mechanism of escape in presence of these bNabs. RESULTS: We have studied the viral population infecting a long term non progressor HIV-1 infected patient who had developed broadly neutralizing antibodies toward all tier 2/3 viruses (6 clades) tested, 9 years after infection, and was then followed up over 7 years. The autologous neutralization titers of the sequential sera toward env variants representative of the viral population significantly increased during the follow-up period. The most resistant pseudotyped virus was identified at the last visit suggesting that it represented a late emerging escape variant. We identified 5 amino acids substitutions that appeared associated with escape to broadly neutralizing antibodies. They were V319I/S, R/K355T, R/W429G, Q460E and G/T463E, in V3, C3 and V5 regions. CONCLUSION: This study showed that HIV-1 may continue to evolve in presence of both broadly neutralizing antibodies and increasing autologous neutralizing activity more than 10 years post-infection. Public Library of Science 2012-08-30 /pmc/articles/PMC3431314/ /pubmed/22957000 http://dx.doi.org/10.1371/journal.pone.0044163 Text en © 2012 Chaillon et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Chaillon, Antoine
Braibant, Martine
Hué, Stéphane
Bencharif, Samia
Enard, David
Moreau, Alain
Samri, Assia
Agut, Henri
Barin, Francis
Human Immunodeficiency Virus Type-1 (HIV-1) Continues to Evolve in Presence of Broadly Neutralizing Antibodies More than Ten Years after Infection
title Human Immunodeficiency Virus Type-1 (HIV-1) Continues to Evolve in Presence of Broadly Neutralizing Antibodies More than Ten Years after Infection
title_full Human Immunodeficiency Virus Type-1 (HIV-1) Continues to Evolve in Presence of Broadly Neutralizing Antibodies More than Ten Years after Infection
title_fullStr Human Immunodeficiency Virus Type-1 (HIV-1) Continues to Evolve in Presence of Broadly Neutralizing Antibodies More than Ten Years after Infection
title_full_unstemmed Human Immunodeficiency Virus Type-1 (HIV-1) Continues to Evolve in Presence of Broadly Neutralizing Antibodies More than Ten Years after Infection
title_short Human Immunodeficiency Virus Type-1 (HIV-1) Continues to Evolve in Presence of Broadly Neutralizing Antibodies More than Ten Years after Infection
title_sort human immunodeficiency virus type-1 (hiv-1) continues to evolve in presence of broadly neutralizing antibodies more than ten years after infection
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3431314/
https://www.ncbi.nlm.nih.gov/pubmed/22957000
http://dx.doi.org/10.1371/journal.pone.0044163
work_keys_str_mv AT chaillonantoine humanimmunodeficiencyvirustype1hiv1continuestoevolveinpresenceofbroadlyneutralizingantibodiesmorethantenyearsafterinfection
AT braibantmartine humanimmunodeficiencyvirustype1hiv1continuestoevolveinpresenceofbroadlyneutralizingantibodiesmorethantenyearsafterinfection
AT huestephane humanimmunodeficiencyvirustype1hiv1continuestoevolveinpresenceofbroadlyneutralizingantibodiesmorethantenyearsafterinfection
AT bencharifsamia humanimmunodeficiencyvirustype1hiv1continuestoevolveinpresenceofbroadlyneutralizingantibodiesmorethantenyearsafterinfection
AT enarddavid humanimmunodeficiencyvirustype1hiv1continuestoevolveinpresenceofbroadlyneutralizingantibodiesmorethantenyearsafterinfection
AT moreaualain humanimmunodeficiencyvirustype1hiv1continuestoevolveinpresenceofbroadlyneutralizingantibodiesmorethantenyearsafterinfection
AT samriassia humanimmunodeficiencyvirustype1hiv1continuestoevolveinpresenceofbroadlyneutralizingantibodiesmorethantenyearsafterinfection
AT aguthenri humanimmunodeficiencyvirustype1hiv1continuestoevolveinpresenceofbroadlyneutralizingantibodiesmorethantenyearsafterinfection
AT barinfrancis humanimmunodeficiencyvirustype1hiv1continuestoevolveinpresenceofbroadlyneutralizingantibodiesmorethantenyearsafterinfection